Hybrid QM/MM calculations on adducts of five platinum-based anti-cancer drugs, namely cisplatin, oxaliplatin, lobaplatin, and heptaplatin are reported. Starting from the NMR structure of a cisplatin–DNA octamer complex (PDB entry 1AU5), we compare DNA binding of drugs that differ in their carrier ligands, and hence in their potential interactions with DNA. It is shown that all drugs induce broa...

PURPOSE To assess the effect and safety of lobaplatin combinated floxuridine /pirarubicin in transcatheter hepatic arterial chemoembolization(TACE) of unresectable primary liver cancer. PATIENTS AND METHODS TACE combined with the chemotherapy regimen was used to treat 34 unresectable primary liver cancer patients. DSA/ MRI/CT/blood routine examinations were used to evaluate short term activit...

A series of chiral cyclometalated platinum(II) complexes, [Pt((-)-L1)(Dmpi)]Cl ((-)-1), [Pt((+)-L1)(Dmpi)]Cl ((+)-1), [Pt((-)-L2)(Dmpi)]Cl ((-)-2), [Pt((+)-L2)(Dmpi)]Cl ((+)-2), [Pt3((-)-L2)2(Dmpi)4](ClO4)4 ((-)-3), and [Pt3((+)-L2)2(Dmpi)4](ClO4)4 ((+)-3) [(-)-L1 = (-)-4,5-pinene-6'-phenyl-2,2'-bipyridine, (+)-L1 = (+)-4,5-pinene-6'-phenyl-2,2'-bipyridine), (-)-L2 = (-)-1,3-bis(2-(4,5-pinene)p...

The role of glutathione (GSH) in the effectiveness of and resistance to 7 platinum compounds [5 Pt(II) and 2 Pt(IV) drugs] was evaluated in a 8.6-fold cisplatin (CDDP)-resistant human small cell lung cancer cell line (GLC4/CDDP), the parent GLC4 line, a 3.7-fold CDDP-resistant human embryonal carcinoma cell line (Tera-CP), and the parent Tera line (NTera2/D1). Resistance factors for both CDDP-r...

The synthesis and optical properties of several phosphorescent conjugated poly(phenylene)s containing cyclometalated square-planar platinum (II) complexes are reported. These electronic polymers were synthesized via Suzuki cross-coupling of a dibromophenylpyridine-ligated Pt(II) complex with a fluorene diboronic ester. Their optical properties are characterized by relatively strong orange room-...